Nicola Burgess-Brown

Nicola Burgess-Brown

SGC UCL

Burgess-Brown

Nicola Burgess-Brown

nburgessbrown@thesgc.org

Biography

Nicola Burgess-Brown was born in Northern Ireland. After graduating with a degree in biochemistry from the University of Ulster, she moved to SmithKline Beecham where she worked for 1 year before pursuing a PhD in Molecular Microbiology at Nottingham, also sponsored by SB. She then moved to Oxford GlycoSciences, in a team that aimed to identify and validate novel oncology targets for generating therapeutic antibodies. Nicola returned to academia to the University of Oxford to lead a team in Biotechnology within the Structural Genomics Consortium. Over the course of 17 years, working in a highly collaborative environment, her team developed cutting edge technologies and high-throughput (HTP) platforms to express a plethora of very challenging human proteins for structural and functional analyses. From September 2021, she led the Enzymology and Protein Engineering Team at Exact Sciences Innovation in Oxford, producing proteins for cancer diagnostic research. Since January 2024, she rejoined the SGC, working as a consultant (Chief Operating Officer, Protein Sciences) coordinating protein production across the 6 SGC sites and, from April 2025, became a Professorial Research Fellow in Protein Sciences at UCL. 

Research Areas

Nicola's research interests include developing novel technologies to express and purify proteins for many applications including drug discovery, cancer diagnostics and vaccine development. She is interested in finding new methods for tackling highly challenging proteins, and at Oxford, developed methodologies for expressing and purifying human integral membrane proteins. She is also keen to work on targets involved in antimicrobial resistance, having studied quorum sensing during her PhD. Throughout her career, she has enjoyed collaborative research which has enabled productive interactions with colleagues in academia and industry partners.

2020

The RESOLUTE consortium: unlocking SLC transporters for drug discovery.

Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gürtl B, Klavins K, Klimek C, Lindinger S, Liñeiro-Retes E, Müller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, Hepworth D, Liu S, Noell S, Piotrowski M, Stanton R, Zhang H, Corallino S, Faedo A, Insidioso M, Maresca G, Redaelli L, Sassone F, Scarabottolo L, Stucchi M, Tarroni P, Tremolada S, Batoulis H, Becker A, Bender E, Chang YN, Ehrmann A, Müller-Fahrnow A, Pütter V, Zindel D, Hamilton B, Lenter M, Santacruz D, Viollet C, Whitehurst C, Johnsson K, Leippe P, Baumgarten B, Chang L, Ibig Y, Pfeifer M, Reinhardt J, Schönbett J, Selzer P, Seuwen K, Bettembourg C, Biton B, Czech J, de Foucauld H, Didier M, Licher T, Mikol V, Pommereau A, Puech F, Yaligara V, Edwards A, Bongers BJ, Heitman LH, IJzerman AP, Sijben HJ, van Westen GJP, Grixti J, Kell DB, Mughal F, Swainston N, Wright-Muelas M, Bohstedt T, Burgess-Brown N, Carpenter L, Dürr K, Hansen J, Scacioc A, Banci G, Colas C, Digles D, Ecker G, Füzi B, Gamsjäger V, Grandits M, Martini R, Troger F, Altermatt P, Doucerain C, Dürrenberger F, Manolova V, Steck AL, Sundström H, Wilhelm M, Steppan CM

Nat Rev Drug Discov. 2020-4-7 . .doi: 10.1038/d41573-020-00056-6

PMID: 32265506

2019

The structural basis of lipid scrambling and inactivation in the endoplasmic reticulum scramblase TMEM16K.

Bushell SR, Pike ACW, Falzone ME, Rorsman NJG, Ta CM, Corey RA, Newport TD, Christianson JC, Scofano LF, Shintre CA, Tessitore A, Chu A, Wang Q, Shrestha L, Mukhopadhyay SMM, Love JD, Burgess-Brown NA, Sitsapesan R, Stansfeld PJ, Huiskonen JT, Tammaro P, Accardi A, Carpenter EP

Nat Commun. 2019-9-2 . 10(1):3956 .doi: 10.1038/s41467-019-11753-1

PMID: 31477691

High-Throughput Site-Directed Mutagenesis.

Strain-Damerell C, Burgess-Brown NA

Methods Mol. Biol.. 2019-7-4 . 2025:281-296 .doi: 10.1007/978-1-4939-9624-7_13

PMID: 31267458

2018

Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design.

Dong YY, Wang H, Pike ACW, Cochrane SA, Hamedzadeh S, Wyszyński FJ, Bushell SR, Royer SF, Widdick DA, Sajid A, Boshoff HI, Park Y, Lucas R, Liu WM, Lee SS, Machida T, Minall L, Mehmood S, Belaya K, Liu WW, Chu A, Shrestha L, Mukhopadhyay SMM, Strain-Damerell C, Chalk R, Burgess-Brown NA, Bibb MJ, Barry Iii CE, Robinson CV, Beeson D, Davis BG, Carpenter EP

Cell. 2018-11-1 . 175(4):1045-1058.e16 .doi: 10.1016/j.cell.2018.10.037

PMID: 30388443

2017

The SGC beyond structural genomics: redefining the role of 3D structures by coupling genomic stratification with fragment-based discovery.

Bradley AR, Echalier A, Fairhead M, Strain-Damerell C, Brennan P, Bullock AN, Burgess-Brown NA, Carpenter EP, Gileadi O, Marsden BD, Lee WH, Yue W, Bountra C, von Delft F

Essays Biochem.. 2017-11-8 . 61(5):495-503 .doi: 10.1042/EBC20170051

PMID: 29118096

Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.

Tumber A, Nuzzi A, Hookway ES, Hatch SB, Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C, Szykowska A, Wu N, Bountra C, Strain-Damerell C, Burgess-Brown NA, Ruda GF, Fedorov O, Munro S, England KS, Nowak RP, Schofield CJ, La Thangue NB, Pawlyn C, Davies F, Morgan G, Athanasou N, Müller S, Oppermann U, Brennan PE

Cell Chem Biol. 2017-2-27 . .doi: 10.1016/j.chembiol.2017.02.006

PMID: 28262558

2016

Structure of the polycystic kidney disease TRP channel Polycystin-2 (PC2).

Grieben M, Pike AC, Shintre CA, Venturi E, El-Ajouz S, Tessitore A, Shrestha L, Mukhopadhyay S, Mahajan P, Chalk R, Burgess-Brown NA, Sitsapesan R, Huiskonen JT, Carpenter EP

Nat. Struct. Mol. Biol.. 2016-12-19 . .doi: 10.1038/nsmb.3343

PMID: 27991905

Structural analysis of human KDM5B guides histone demethylase inhibitor development.

Johansson C, Velupillai S, Tumber A, Szykowska A, Hookway ES, Nowak RP, Strain-Damerell C, Gileadi C, Philpott M, Burgess-Brown N, Wu N, Kopec J, Nuzzi A, Steuber H, Egner U, Badock V, Munro S, LaThangue NB, Westaway S, Brown J, Athanasou N, Prinjha R, Brennan PE, Oppermann U

Nat. Chem. Biol.. 2016-5-23 . .doi: 10.1038/nchembio.2087

PMID: 27214403

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.

Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J

J. Med. Chem.. 2016-1-7 . .doi: 10.1021/acs.jmedchem.5b01635

PMID: 26741168

2015

Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis.

Montgomery AB, Kopec J, Shrestha L, Thezenas ML, Burgess-Brown NA, Fischer R, Yue WW, Venables PJ

Ann. Rheum. Dis.. 2015-7-24 . .doi: 10.1136/annrheumdis-2015-207656

PMID: 26209657